info@cartglobalconsultant.com




Making your
Cell and Gene Therapy Assets
a Reality

CAR T Global Consultant Inc. is a boutique consulting company that focuses on supporting the commercialization of Cell and Gene Therapies.
Uniqueness

The Uniqueness of Cell and Gene Therapy

The uniqueness associated to Cell and Gene Therapy is due to an extensive list of variables, such as high COGS, just-in-time manufacturing, sophisticated HTA submissions, health systems readiness, patient choice, individualized QC and QA release, forecast capacity, initial high infrastructure investments and a flawless ordering system.

The complexity level and the risks are high – applying the blueprint of a traditional pharmaceutical launch plan does not translate well in this environment. Although certain knowledge and skillsets from other pharmaceutical launches are transferrable, a new skills set is needed to create profitable commercialization plan.

CAR T Global Consultant is a firm that specializes in the commercialization of Cell and Gene Therapy Assets. Whether your company has assets in Phase 1 or has approved Cell and Gene Therapy products, we have the expertise to support your company aspirations. Our mission is to make your asset a reality.

Team

Our Team

We have a strong network of talented individuals with specific expertise in CAR T. Depending on the scope of the project, we will bring in the best experts to support your goals. All projects will be handcrafted and fully executed by our lead executive consultant.



Guillaume Koszegi

About

Guillaume Köszegi

A few words about the founder

Guillaume Köszegi, Founder and President of CAR T Global Consultant, opened this global boutique Cell and Gene Therapy consulting company in 2021. He has over two decades of experience in increasingly complex roles at leading Cell and Gene Therapy companies. These roles include and are not limited to:

  • Country Head of CAR T Marketing
  • Head CAR T Operations
  • National Market Access Innovative Solutions
  • Early Asset Pipeline Commercial Lead



Guillaume has built a vast and deep network of Cell and Gene Therapy experts, leaders, and collaborators. As such, each project completed by CAR T Global Consultant is tailored to meet your highly individual needs.



Customers

Our Customers

Whether your company has assets in Phase 1 or has approved Cell and Gene Therapy products, we have the expertise to support your company aspirations.

We understand that if you are a small Biotech, you’ll have specific needs to strengthen and secure your commercialization pathways. We also understand that if you are part of a bigger pharmaceutical company with current marketed assets and others in the pipeline, you have different priority needs such as product differentiation, best-in-class execution, and KOL engagement.





men

Our Consultancy Services


As a new global boutique Cell and Gene Therapy consulting company, we successfully support projects in cutting edge scientific fields such as CAR T, TCR, AAV Gene Therapy, ADCs and CAR T Manufacturing Programs.

Projects have included:

• Blueprint for commercial organization readiness:

- Go-to-Market strategic planning

- Resource allocations
- FTE strategic role identification
- Scalable field model
- Timeline mapping
- Centers/Hospital prioritization


• Blueprint for Commercial launch of CGT in North America and EU

- Market Assessment
- Marketing Plan
- Medical Plan
- Hospital Readiness Plan
- Market Access Plan
- Resource, timeline and milestone identification


• Identification of customers

- Identify Key Opinion Leaders
- Customer segmentation


• Identify hospitals with high patient volume

- Tiering of hospitals
- Mapping of activated CAR T sites

• Creation of the Customer Engagement Plan
• Tactical implementation of the Customer Engagement Plan

- Access to Key Opinion Leaders
- Ad Board development and moderation
- Strategic Council with Key Opinion Leaders

- One on One discussions

- Interviews at International Conferences

- Primary Investigators who present pivotal data
- Discussion Guide, Interview, Video creation

- In-depth Key Opinion Leader mapping/targeting

Consultancy

Our Consultancy Service Model

Our integrated services ensure that whatever your needs, we have the right Lead Expert Consultant to support you.


men

We have a strong, global network of talented individuals with specific expertise in Cell and Gene Therapy. Depending on the scope of the project, we will bring in the best experts to support your goals. All projects will be handcrafted and fully executed by our Lead Executive Consultant.
CGT CCO SERVICES

Our Contract Commercialization Organization Services specifically designed for Cell and Gene Therapies (CTG CCO)

Our CGT CCO is an innovative hybrid approach to commercialization, allowing your company to maintain control while maximizing the internal value of your assets.

Conventionally there are only 2 options: out-license / sell your assets to a larger firm or build a full commercialization structure. The latter requires extensive resources and expertise that most Biotech companies are often lacking. Our hybrid model offers Biotech the option to keep your assets and outsource the commercialization services – either until an identified milestone is met, or for as long as you deemed required. You maintain control while maximizing the internal value of your assets.

The logistical, technical, scientific and regulatory requirements of Cell & Gene therapies are very specific. We will find and train the staff with these qualifications in the targeted country or region. We will then support a flawless omnichannel execution. Our CGT Contract Commercialization Organization will provide best-in-class teams with the required expertise in areas including and not limited to: Medical Affairs, Sales, Site Onboarding, Market Access and Regulatory Affairs. The full-service Cell & Gene Therapy specific Contract Commercialization Organization (CGT CCO) offers a cost-efficient commercial option, bringing these important assets to patients without delay.

Find out more




  • February 22, 2024

CAR T Global Consultant announces that cell therapy senior executive Michael DeRidder, PhD, has joined as a Partner to enhance capabilities as we launch the first Contract Commercialization Organization in Cell and Gene Therapies (CCO CGT).


Guillaume Koszegi

Mike DeRidder, Partner
CAR T Global Consultant Inc.

MONTREAL, QC – February 22, 2024 – CAR T Global Consultant Inc., a specialized Cell & Gene Therapy consulting company, announces the appointment of Michael DeRidder, PhD, as Partner specializing in commercial, strategic, and business development consulting for companies in cell and gene therapies. Dr. DeRidder’s extensive experience, most recently as SVP Corporate Strategy and New Product Planning at Catamaran Bio and previously as Vice President, Medicine Commercialization Leader for Cell and Gene Therapies at GlaxoSmithKline (GSK), will deepen CAR T Global Consultant Inc.’s capabilities and service offerings to cell and gene therapy companies.

“I am thrilled to have Mike join our team. Mike’s extensive industry knowledge will strengthen our capabilities when providing consulting and strategic advice. I see an important opportunity to leverage his senior leadership capabilities as we support companies via our CCO CGT offerings. His expertise across a range of disease areas is timely as Cell and Gene therapies are quickly evolving beyond hematologic malignancies.” Guillaume Köszegi, Founder of CAR T Global Consultant Inc.


“I am excited by the opportunity to utilize my experience in order to help biotech and pharma organizations to advance their cell and gene therapy assets to the market,” said Dr. DeRidder. “It is an exciting time in the cell and gene therapy space as more therapies reach the market and the breadth of applications of this potentially curative technology continues to expand.”

In Dr. DeRidder’s previous role at Catamaran Bio, he was responsible for leading the business development and portfolio strategy for the company’s allogeneic NK cell therapies against solid tumors. Prior to this, Dr. DeRidder spent over 10 years at GSK, where he was responsible for planning the global launch strategy for letetresgene autoleucel (lete-cel), an engineered T cell therapy currently in pivotal clinical development. He also played a leadership role in the operational design and implementation of GSK’s cell therapy capabilities and the cell therapy portfolio strategy. In addition, he played a leading role in the company’s $5 billion acquisition of Tesaro in 2019 and the in-licensing of the NY-ESO-1 TCR program from Adaptimmune.

Earlier in his time at GSK, Dr. DeRidder held positions of increasing responsibility in New Product Planning and Business Development across a range of disease areas including Neuroscience, Rare Disease, and Ophthalmology.

Dr. DeRidder began his career as an Engagement Manager at L.E.K. Consulting.

He holds a PhD in Biomedical Engineering from the University of Pennsylvania and a BSE in Bioengineering from Tulane University.

  • January 17, 2024

CAR T Global Consultant Inc. Announces the launch of the first ever Full Service Contract Commercialization Organization specifically designed for Cell & Gene Therapy (CGT CCO)


Montreal, January 17, 2024 /PRNewswire/- CAR T Global Consultant Inc. - a specialized Cell & Gene Therapy consulting company announces their newest offering in the form of a Contract Cell & Gene Therapy Organization that will provide Biotech companies a comprehensive go-to-market commercialization service while retaining their intellectual property.

Guillaume Köszegi, Founder and President of CAR T Global Consultant observes: “Commercialization options for Biotechs are limited. Conventionally there are only 2 options: out-license / sell their asset to a larger firm or build a commercialization structure on their own. The latter requires extensive resources and expertise that most Biotech companies are often lacking. We see an opportunity to support companies with a hybrid model that allows them to keep their assets and outsource the commercialization services – either until an identified milestone is met, or for as long as is deemed required. In this fast-paced environment, companies can re-invest in R&D rather than the build out of a commercial organization. They maintain control while maximizing the internal value of their assets”.

Furthermore, Mr. Köszegi explains that: “The logistical, technical, scientific and regulatory requirements of Cell & Gene therapies are very specific. Finding and training staff with these qualifications in each specific country∕region can be difficult. Our CGT Contract Commercialization Organization will provide best-in-class teams with the required expertise in areas including and not limited to: Medical Affairs, Sales, Site Onboarding, Market Access and Regulatory Affairs.”

There are currently 1369 cell and gene therapy developers worldwide generating over 2000 ongoing clinical trials. The majority of these trials are in Phase 2 and Phase 3. There is an expected bolus of novel agents to treat numerous niched disease populations. The expertise from specialized companies like CAR T Global Consultant Inc. will play a major role in ensuring these molecules reach the market in a timely and efficient manner.

CAR T Global Consultant Inc. is proud to further elevate our mission of supporting cell & gene therapy organizations via this Full-Service Cell & Gene Therapy Specific Contract Commercialization Organization (CGT CCO) so that with flawless execution, they may bring their important assets to patients without delay.


  • April 5, 2023

COMPANY OF THE YEAR: Life Science Review Magazine’s Special Canadian 2023 Therapeutics Edition



  • December 7, 2022

CAR T Global Consultant Inc. Announce their Collaboration with Titronbio - a company founded in Shanghai China by a renowned leader in the field of CAR T and Cell and Gene therapy


MONTREAL and SHANGHAI, Dec. 7, 2022 /PRNewswire/ - CAR T Global Consultant Inc. - a specialized cell therapy consulting company and Titronbio (TM) - a company specialized in Cell and Gene therapy and CAR T announcing their collaboration. This joint venture will allow them to strengthen their position in the consultation field of cell and gene therapy.

"The Joint venture between CAR T Global Consultant and Titronbio will enhance our portfolio to support more Cell and Gene companies. Titronbios founder brings an impressive background of successful scientific, regulatory, and medical development experience that will allow us to better guide our customers through all stages of development. Our goal is to make the Cell and Gene therapies products of our customers, a reality." - G. Köszegi, President and founder of CAR T Global Consultant Inc.

"I am thrilled to announce the collaboration with CAR T Global consultant. There is an increasing number of players in the CAR T field however the critical experience and expertise needed to navigate the challenging development ultimately leading to successful product launches is often lacking. Our collaboration is poised to support those companies in need of specific expert knowledge to help guide them on their path to success."

- Dr Sersch MD, PhD, President and founder.



About Titronbio (TM)

Titronbio (TM) was founded in 2022 in Shanghai, China by a leading expert in the field of cell and gene therapy including CAR T. The company's goal it to enhance the support of promising cell and gene companies by bringing senior executive expertise to enhance their portfolio's development. The knowledge was achieved through an impressive track record of holding various executive positions at MNC companies including Genentech and Amgen and most recently in the function of Chief Medical Officer for NASDAQ listed cell and gene therapy companies, leading successful clinical development strategies in solid and liquid tumors including Multiple Myeloma. In addition, part of the experience includes C series funding and successful initial Public Offering (IPO) on NASDAQ. Of note, Dr Sersch's concise medical leadership led to the execution of multiple Investigator Initiated Trial (IIT) studies, including frontline MM, with one of the first fast CAR T manufacturing processes where data in frontline Multiple Myeloma will be presented at this year ASH conference as an oral abstract presentation: "Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma". For more information about the company please visit www.Titronbio.com



About CAR T Global Consultant Inc.

CAR T Global Consultant is a privately held global consulting company founded in 2021. The company primary focuses on supporting cell therapy companies through their commercial development path. CAR T Global Consultant holds two main division, one aimed towards early commercialization efforts and the other towards clinical operations. CAR T Global Consultant is uniquely positioned as it possesses a strong network of talented industry leaders with specific Cell therapy expertise. The company established a business model that builds consultant teams tailored for each individual project. For more information on CAR T Global Consultant please visit www.CARTGlobalConsultant.com

Click here to read on CISION PR Newswire
PRNewsWire